Workflow
Genfit(GNFT)
icon
Search documents
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting
GlobeNewswire· 2025-02-21 07:30
Put Option Agreements signed to date with 2025 OCEANEs holders representing 95.3% of the outstanding 2025 OCEANEs2025 OCEANEs holders' general meeting convened for March 10, 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 2025 OCEANEs ho ...
GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders
GlobeNewswire· 2025-02-14 21:10
In conjunction with (i) the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, and (ii) the final terms of the dual proposal to the 2025 OCEANEs holders announced on February 10, 2025, GENFIT will seek the consent of the holders of 2025 OCEANEs and proposes to amend such final terms so as to: repurchase the 2025 OCEANEs at EUR 32.75 per bond from interested bondholders, or alternativelypay a consent fee of EUR 0.90 per bond still outstanding after the upcoming bondholder me ...
GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders
GlobeNewswire· 2025-02-10 06:30
Core Viewpoint - GENFIT has announced the final terms for a dual proposal to the holders of its 2025 OCEANEs, which includes a repurchase offer and a consent fee, following a non-dilutive capped royalty financing agreement with HealthCare Royalty for up to €185 million [2][19]. Group 1: Royalty Financing and Cash Runway - The Royalty Financing agreement with HealthCare Royalty (HCRx) allows GENFIT to extend its cash runway significantly, even after repaying its convertible bonds due on October 16, 2025 [2]. - HCRx will be compensated through a portion of the royalties from the sales of Iqirvo® (elafibranor) under a strategic partnership with Ipsen [3]. Group 2: Terms of the 2025 OCEANEs - The 2025 OCEANEs contain a negative pledge clause that restricts GENFIT from granting security interests on its assets, which necessitates an amendment for the Royalty Financing to proceed [4]. - GENFIT proposes to repurchase the 2025 OCEANEs at €32.00 per bond or alternatively pay a consent fee of €0.60 per bond for those still outstanding after the bondholder meeting [7][8]. Group 3: Consent and Repurchase Process - The repurchase and consent fee proposals are contingent upon the approval of the Amendment of Terms by the general meeting of the 2025 OCEANEs holders and the closing of the Royalty Financing [9][13]. - Holders who do not enter into the Put Option Agreement or do not exercise their option will receive the consent fee after the repurchase [9][11]. Group 4: Future Steps and Meetings - GENFIT plans to convene a general meeting of the 2025 OCEANEs holders in early March to discuss the proposals, with a Consent Solicitation Memorandum to be published [13]. - The results of the general meeting and the closing of the Royalty Financing will be communicated in subsequent press releases [13].
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
GlobeNewswire· 2025-02-06 21:10
2 new ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b also expected by year-end 2025 for GNS561/trametinib in KRAS-mutated cholangiocarcinoma, to support dose selection for Phase 2 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 6, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improvin ...
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
GlobeNewswire· 2025-01-30 07:40
GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital: €130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestonesClosing subject to approval by the 2025 OCEANE bondholders at upcoming bondholders meetingFinancing would extend cash runway beyond the end of 2027, assuming drawdown of all instalmentsProceeds to further strengthen the development of the ACLF pipeline In return, HCR ...
GENFIT Announces 2025 Financial Calendar
GlobeNewswire News Room· 2025-01-29 21:10
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2025. 2025 Financial Calendar February 27, 2025 Publication of revenue and cash position at December 31, 2024 April 24, 2025 Publication of Full Year 2024 financial statements   The 2024 ...
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
GlobeNewswire News Room· 2024-11-13 21:10
PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with expectations; encouraging feedback from healthcare providers and payers in the U.S.UK NICE reimbursement approved and first reimbursed sales in Germany in October 2024Next €26.5M milestone payment by Ipsen pending a third pricing and reimbursement approval in Europe Scientific progress in ACLF to be featured at The Liver Meeting® 2024, with 4 posters presenting n ...
GENFIT Reports Third Quarter 2024 Financial Information
GlobeNewswire News Room· 2024-11-07 21:10
Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® (elafibranor) in the U.S. for the treatment of Primary Biliary Cholangitis (PBC)  Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland); November 7, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical ...
Genfit(GNFT) - 2024 Q2 - Quarterly Report
2024-09-19 20:12
| --- | --- | |-------|---------------------------------------------| | | | | | and Financial Report at June 30, 2024 | Table of Contents | --- | --- | --- | |-------|-------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | 1. | OVERVIEW OF THE GROUP AND ITS MAIN R&D PROGRAMS | 2 | | 2. | HALF-YEAR MANAGEMENT REPORT | 4 | | 2.1 | Key Events of the First Half of 2024 and Main Events after the Reporting Period | 4 | | 2.2 | Strate ...
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
GlobeNewswire News Room· 2024-07-09 20:10
131,000 shares €700 885.51 On the buy side: 2,256 On the sell side: 2,012 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) July 9, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. During this same period, the number of trades were: ABOUT GENFIT and our con ...